Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Spire Healthcare Group Plc | SPI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.60 | 0.35% | 172.00 | 16:35:10 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 171.00 | 170.40 | 172.20 | 172.00 | 171.40 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 06/03/2025 | Interim | GBP | 0.023 | 22/05/2025 | 23/05/2025 | 20/06/2025 |
| 29/02/2024 | Final | GBP | 0.021 | 23/05/2024 | 24/05/2024 | 21/06/2024 |
| 02/03/2023 | Final | GBP | 0.005 | 25/05/2023 | 26/05/2023 | 23/06/2023 |
| Top Posts |
|---|
Posted at 23/3/2025 09:33 by masurenguy Simply Wall StreetSun 23 Mar 2025 Spire Healthcare Group: SPI Last Price: £1.74 * Consensus EPS estimates fall by 15% * The consensus outlook for fiscal year 2025 has been updated. * 2025 EPS estimate fell from UK£0.132 to UK£0.112 per share. * Revenue forecast steady at UK£1.60b. * Net Inc forecast to grow 81% next year vs 28% growth forecast for Healthcare industry in the UK. * Consensus price target down from UK£3.01 to UK£2.91. * Share price was steady at UK£1.74 over the past week. |
Posted at 14/3/2025 17:34 by igoe104 I see paul Hill from vox markets has taken up a position in SPI, he mentioned the assets are worth a hell of alot more than the current shareprice... |
Posted at 06/3/2025 15:09 by peterbill From Morningstar, not sure if it's been updated. P/E ratio still too high. Combined with NI and Tax increases, this could fall further.Dividend yield 0.94%Market capitalisation £745.33 mnP/E ratio 33.01 |
Posted at 06/3/2025 13:17 by masurenguy New 4 year low. This share was recommended as his best stock idea of 2025 by Christopher Mills, talking to Paul Hill circa 7 weeks ago when the shareprice was 237p. Just goes to show that nobody has infallible wisdom where the stock market is concerned even when they have a much closer insight into the business than is possible for any external investors."I don't frankly see a lot of downside on this because we know that the business is performing well. We know that the demand is sitting there and the dividend is going to go up a lot and the share is going to go up a lot. I kinda see it as a one way bet really." Christopher Mills of Harwood Capital, 15 January. |
Posted at 06/3/2025 08:40 by deanowls Look on the bright side. Dividend yield has shot up!I’d imagine the largest shareholder may wish to buy it. |
Posted at 06/3/2025 07:13 by masurenguy Spire Healthcare reports results for the year ended 31 December 2024Good financial results, strong patient satisfaction and all core metrics in line with guidance Delivered guidance, mitigating mix and cost (Unless otherwise stated, y/y growth metrics and margin expansion metrics are presented on a comparable basis1) · Revenue growth of 6.2% y/y; comprised of 5.5% y/y in Hospitals and 15.0% y/y from Primary Care services. · Payor mix evolving with stronger performance in NHS revenue, up 8.8% y/y and Private patient revenue (PMI + Self-Pay) up 4.3% y/y. · Group adj. EBITDA grew 9.0% to £260.0m. Reflecting price, acuity and cost saving benefits which provided mitigation to H2 impacts from payor mix changes and energy hedge roll off. · Group adj. EBITDA margin of 17.2%. Within this, we saw good expansion in Hospitals margin, up 30 bps y/y to 18.0% and very strong expansion in Primary Care margin up 340 bps to 8.5%. · Operating profit up 9.0% y/y on a stated basis to £137.5m, including adjusting items of £(11.9)m largely related to the transformation programme and previously disclosed remediation. · ROCE(6) increased to 8.2% (FY23: 7.5%). · Recommended final dividend of 2.3 pence per ordinary share (FY23: 2.1 pence per ordinary share). Strong strategic delivery of growth and efficiency · Cost savings accelerated: delivering >£20m in FY24 through procurement standardisation, automating booking procedures, Patient Support Centres and implementing staffing models to reduce agency use. · Vita outperforming management expectations with revenue of £107m and EBITDA £11m. · Three new Primary Care clinics opened. Meeting more patient needs and driving referrals to nearby Hospitals. · Responded to NHS demand. Increasing eRS slots and driving 20% y/y volume growth in Q4, with high Orthopaedic mix of over 60%. · Record levels of clinical permanent employment, with turnover at an all-time low of 11.5%. · Leading on quality. Average length of stay reduced for hip and knee procedures, Patient Safety Incident Response Framework implemented and Patient Survey showed 97% rated their experience as good / very good (up 1% from prior year). Outlook and current trading We are confident in delivering mid-single digit y/y percentage Group revenue growth in FY25. This will be driven by the combination of structural market expansion, good growth prospects in Hospitals and the growing demand for our Primary Care services. We continue to see evolution in the underlying mix by payor group. We anticipate strong overall demand for services, with growth in Private patients and a continued strategic partnership with the NHS. The growth in Private patients will be driven by Private Medical Insurers (PMIs), where they are reporting strong increases in policies written, which in turn will result in more activity; and working age patients increasingly being covered. The latter means we anticipate continued Self Pay (SP) switching to PMI, where our drivers for growth are focused on average revenue per case (ARPC) and mix management. As a reminder, share price procedures are our highest margin activities, followed by PMI, and NHS funded admissions. Cost savings are already delivering ahead of plan and we intend to accelerate this further. With new savings of at least £30m in FY25, which are c£10m above our original plans. At the same time we are increasing our FY24-26 cumulative savings target to £80m (was previously £60m). We expect a £(30)m EBITDA impact in FY25 as a result of National Insurance (NI) and National Minimum Wage (NMW), payor mix changes and the roll off of our energy hedge. We expect NI and NMW to add £18-20 million to operating costs on an annualised basis before mitigation, making the FY25 in-year impact c£13-15m. In FY25 we believe we can offset c£10m of NI, NMW, payor mix and energy costs combined through accelerated cost savings, driving high margin acuity mix and self-pay pricing changes. Bringing this together, we are guiding to FY25 adjusted EBITDA for the Group to be in the range of £270m to £285m. We remain committed to our medium-term financial targets. We continue to forecast ongoing revenue growth of greater than 5% for the Hospitals business. Vita is delivering ahead of plan and newly opened Spire Clinics are sending downstream revenue to nearby Hospitals. Our ambition is for Primary Care to become a >£40m EBITDA business in the medium term, delivered through significant contract wins in Mental Health/Occupational Therapy, more new Clinic openings and small M&A. Combining this together with accelerated savings, we expect to be able to neutralise NI/NMW and payor mix changes fully by 2027, enabling delivery of our medium-term ROCE and Hospital margin targets. Spire Healthcare has traded in-line with our expectations since the year end. Justin Ash, CEO of Spire Healthcare, said: "This is a good set of results, delivering all core guidance measures in a changing market. We saw revenue growth of 6.2% year-on-year and adjusted profit before tax growing 29.4%. Market fundamentals remain strong, with private medical insurance coverage growing significantly and a strong partnership with the NHS. Our strategy is delivering. We broadened our range of services to meet more healthcare needs in our hospitals, our clinics, in the community and at home; welcomed more NHS patients and invested significantly in our Hospital staff. We are playing a pivotal role in helping employees stay in work or return to work; all whilst maintaining and improving our quality of care and levels of patient safety, which remain our number one priorities. I thank all our colleagues and consultant partners for their expertise and commitment. We are excited about the future. We remain confident in the combination of structural market growth, supplemented by the potential of new Primary Care services to complement our hospitals, and a continued strategic partnership with the NHS helping to deliver waiting list reductions. In the year ahead, we will see pressure on costs as a result of National Insurance and Minimum Wage changes. However, we already have a successful efficiencies programme in place and intend to drive self-help measures even faster, partly offsetting the impact to operating costs. I am excited about our prospects for 2025 and we look forward to contributing in even greater measure to the nation's health." |
Posted at 13/2/2025 01:54 by yasx An improved dividend might help. |
Posted at 24/10/2024 11:00 by mongrels4 Jefferies raises #SPI Spire PT to 278 (250)buy |
Posted at 03/11/2023 16:44 by petersinthemarket FWIW – That guy Robbie Burns (aka Naked Trader) said the following on his thread yesterday.''I've added some more Spire: it's made what looks a decent acquisition of the Vita Health Group. Spire always seems to have a massive debt but this is ok here as it has a ton of property assets that more than cover the debt pile. This acquisition should make Spire even more valuable and you wonder perhaps next year whether a big US provider might be tempted to take it.'' He has followed the ups/downs of the SPI chart for a few years and currently has three recent buys open at around the 209/213p area. |
Posted at 11/5/2023 07:43 by bonzo1975 Spire Healthcare Group PLC AGM StatementSource: UK Regulatory (RNS & others)TIDMSPIRNS Number : 0236ZSpire Healthcare Group PLC11 May 2023Spire Healthcare Group plc('Spire Healthcare', 'the Group' or 'the Company')AGM STATEMENT11 May 2023Ahead of its Annual General Meeting later today, Spire Healthcare Group plc (LSE: SPI), a leading independent healthcare group in the UK, provides the following update for the period 1 January 2023 to 30 April 2023.The Board is pleased with the Group's performance during the first four months of the year. Consistent with expectations stated in our FY22 results announcement, good momentum has continued from the end of last year. We reiterate our outlook for the full year, as set out in the same announcement.We expect to announce our results for the six months ending 30 June on 14 September 2023.-Ends-For further information please contact: Spire Healthcare +44 (0)20 7427 9000 Angus Prentice - Director of Investor Relations Instinctif Partners +44 (0)20 7457 2020 Damian ReeceGuy ScarboroughRegistere |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
